ACE inhibitors after myocardial infarction — Dr. Busti explains the GISSI-3 trial and what it actually changed in clinical practice on this episode of This Is Why.

After the initial management of acute MI, the real question becomes: what else improves survival and prevents long-term damage? The GISSI-3 trial tackled this directly, evaluating early ACE inhibitor therapy and routine nitrate use in a large, real-world population.

Dr. Busti breaks down how lisinopril provided a modest but meaningful mortality benefit—and why that matters more than it seems. More importantly, we explore the why behind early RAAS blockade, how it impacts ventricular remodeling, and which patients benefit the most.

This is not about memorizing treatment steps—it’s about understanding how small, evidence-based decisions compound to improve patient outcomes.

Topics Covered:
- Why the GISSI-3 trial was needed
- Trial design and 2x2 factorial structure
- Early ACE inhibitor therapy after MI
- Mortality and combined endpoint outcomes
- Absolute vs relative risk reduction
- Why nitrates did not improve survival
- Mechanism of RAAS blockade and remodeling
- High-risk subgroups (diabetes, anterior MI, LV dysfunction)
- Limitations of GISSI-3 in modern practice
- Applying early ACE inhibitors clinically

Chapter Table of Contents
00:00 - Introduction
01:54 - What is the GISSI-3 Trial?
03:25 - Key Results of GISSI-3
04:37 - Interpreting the Data
05:47 - Mechanism of Heart Failure Prevention in GISSI-3
07:59 - Limitations of GISSI-3 & Applying It to Modern Practice
09:24 - Clinical Takeaways
11:37 - Conclusion

#GISSI3Trial #ACEinhibitorsMI #postMIcare #ventricularremodeling #Dr Bust

If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#GISSI3Trial #ACEinhibitorsMI #postMIcare #ventricularremodeling #DrBust

Speaker:
Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education.
Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes.

About This Channel:
This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC).

Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.